Seaport Therapeutics (NASDAQ:SPTX) Stock Breaks Above Fifty Day Moving Average – Here’s What Happened

Seaport Therapeutics, Inc. (NASDAQ:SPTX) shares passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $20.68 and traded as high as $21.75. Seaport Therapeutics shares last traded at $21.50, with a volume of 227,030 shares changing hands.

Key Seaport Therapeutics News

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: Director Denice Torres bought 5,000 shares for about $99,300 at an average price of $19.86, a notable insider purchase that may signal confidence in the company. Article: Seaport Therapeutics Director Purchases Shares
• Positive Sentiment: JPMorgan raised its price target to $41 from $40 and maintained an Overweight rating. HC Wainwright also reiterated its Buy rating and $50 target, reflecting continued analyst optimism, though targets are not guarantees. Seaport Therapeutics analyst information
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it narrowed its projected FY2026 loss to $3.95 per share from $4.09 and improved its Q4 2026 and Q1 2027 estimates, but its Q3 and Q4 2027 estimates imply somewhat larger losses. The revisions are modest and do not change its Buy rating or $50 target.
• Positive Sentiment: Seaport’s latest reported quarterly loss of $0.49 per share was better than the $0.58 loss analysts expected, providing a recent earnings beat that may help cushion concerns about future losses.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group initiated coverage on Seaport Therapeutics in a research report on Wednesday, October 14th. They set a “buy” rating and a $28.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Seaport Therapeutics from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday. Raymond James Financial assumed coverage on shares of Seaport Therapeutics in a research note on Friday, September 25th. They issued a “strong-buy” rating and a $46.00 price target on the stock. JonesTrading initiated coverage on shares of Seaport Therapeutics in a report on Wednesday, August 26th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, UBS Group restated a “buy” rating on shares of Seaport Therapeutics in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.12.

Seaport Therapeutics Stock Performance

The stock’s 50-day simple moving average is $20.68. The firm has a market cap of $1.15 billion and a PE ratio of -1.77.

Seaport Therapeutics (NASDAQ:SPTX) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.09. Equities research analysts anticipate that Seaport Therapeutics, Inc. will post -4.35 EPS for the current fiscal year.

Insider Buying and Selling at Seaport Therapeutics

In other Seaport Therapeutics news, Director Denice Torres bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was acquired at an average price of $19.86 per share, for a total transaction of $99,300.00. Following the completion of the purchase, the director owned 5,000 shares of the company’s stock, valued at approximately $99,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Trading of Seaport Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TRV GP VI LLC purchased a new position in shares of Seaport Therapeutics in the 2nd quarter valued at approximately $44,769,742. Braidwell LP purchased a new stake in shares of Seaport Therapeutics during the second quarter worth approximately $10,860,000. Citadel Advisors LLC purchased a new stake in shares of Seaport Therapeutics during the second quarter worth approximately $4,152,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Seaport Therapeutics during the second quarter worth $1,793,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Seaport Therapeutics during the second quarter worth $1,629,000.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.